Hemothorax cost-effectiveness of therapy
|
Hemothorax Microchapters |
|
Diagnosis |
|---|
|
Treatment |
|
Case Studies |
|
Hemothorax cost-effectiveness of therapy On the Web |
|
American Roentgen Ray Society Images of Hemothorax cost-effectiveness of therapy |
|
Risk calculators and risk factors for Hemothorax cost-effectiveness of therapy |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Irfan Dotani Joanna Ekabua, M.D. [2]
Overview
Lytic Therapy has been tried for retained traumatic hemothorax.
Cost-effective Therapy
Avoiding surgery after treatment with any lytic agent was found to be 87% (95% CI, 81%-92%). Use of tissue plasminogen activator lead to 83% operative avoidance (95% CI, 71%-94%). Other, non-tissue plasminogen activator lytic agents lead to 87% surgery avoidance (95% CI, 82%-93%). Length of stay for patients on lytic therapy was 14.88 days (95% CI, 12.88-16.88) on average. Lytic Therapy could decrease the need for surgical intervention in patients with retained traumatic hemothorax. Randomized controlled trials are indicated to definitively assess the benefit of this therapy.[1]
References
- ↑ Hendriksen BS, Kuroki MT, Armen SB, Reed MF, Taylor MD, Hollenbeak CS (2019). "Lytic Therapy for Retained Traumatic Hemothorax: A Systematic Review and Meta-analysis". Chest. 155 (4): 805–815. doi:10.1016/j.chest.2019.01.007. PMID 30664856.